| A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial Z Yan, J Cao, H Cheng, J Qiao, H Zhang, Y Wang, M Shi, J Lan, X Fei, ... The Lancet Haematology 6 (10), e521-e529, 2019 | 299 | 2019 |
| Potent anti‐leukemia activities of humanized CD19‐targeted Chimeric antigen receptor T (CAR‐T) cells in patients with relapsed/refractory acute lymphoblastic leukemia J Cao, G Wang, H Cheng, C Wei, K Qi, W Sang, LI Zhenyu, M Shi, H Li, ... American journal of hematology 93 (7), 851-858, 2018 | 181 | 2018 |
| Long-term follow-up of combination of B-cell maturation antigen and CD19 chimeric antigen receptor T cells in multiple myeloma Y Wang, J Cao, W Gu, M Shi, J Lan, Z Yan, L Jin, J Xia, S Ma, Y Liu, H Li, ... Journal of Clinical Oncology 40 (20), 2246-2256, 2022 | 100 | 2022 |
| Coagulation disorders after chimeric antigen receptor T cell therapy: analysis of 100 patients with relapsed and refractory hematologic malignancies Y Wang, K Qi, H Cheng, J Cao, M Shi, J Qiao, Z Yan, G Jing, B Pan, ... Biology of Blood and Marrow Transplantation 26 (5), 865-875, 2020 | 84 | 2020 |
| Efficacy and safety of CD19-specific CAR T cell–based therapy in B-cell acute lymphoblastic leukemia patients with CNSL Y Qi, M Zhao, Y Hu, Y Wang, P Li, J Cao, M Shi, J Tan, M Zhang, X Xiao, ... Blood, The Journal of the American Society of Hematology 139 (23), 3376-3386, 2022 | 76 | 2022 |
| Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma Y Wang, C Li, J Xia, P Li, J Cao, B Pan, X Tan, H Li, K Qi, X Wang, M Shi, ... Blood Advances 5 (23), 5290-5299, 2021 | 74 | 2021 |
| Characteristics and risk factors of cytokine release syndrome in chimeric antigen receptor T cell treatment Z Yan, H Zhang, J Cao, C Zhang, H Liu, H Huang, H Cheng, J Qiao, ... Frontiers in Immunology 12, 611366, 2021 | 74 | 2021 |
| MiR-150 impairs inflammatory cytokine production by targeting ARRB-2 after blocking CD28/B7 costimulatory pathway W Sang, Y Wang, C Zhang, D Zhang, C Sun, M Niu, Z Zhang, X Wei, ... Immunology letters 172, 1-10, 2016 | 68 | 2016 |
| Overexpression of the Mesenchymal Stem Cell Cxcr4 Gene in Irradiated Mice Increases the Homing Capacity of These Cells W Chen, M Li, H Cheng, Z Yan, J Cao, B Pan, W Sang, Q Wu, L Zeng, Z Li, ... Cell biochemistry and biophysics 67, 1181-1191, 2013 | 60 | 2013 |
| Anti–G Protein–Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial J Xia, H Li, Z Yan, D Zhou, Y Wang, Y Qi, J Cao, D Li, H Cheng, W Sang, ... Journal of Clinical Oncology 41 (14), 2583-2593, 2023 | 59 | 2023 |
| IL1RAP as a surface marker for leukemia stem cells is related to clinical phase of chronic myeloid leukemia patients K Zhao, LL Yin, DM Zhao, B Pan, W Chen, J Cao, H Cheng, ZY Li, DP Li, ... International journal of clinical and experimental medicine 7 (12), 4787, 2014 | 55 | 2014 |
| Prognostic values of geriatric nutritional risk index (GNRI) and prognostic nutritional index (PNI) in elderly patients with Diffuse Large B-Cell Lymphoma D Yan, Z Shen, S Zhang, L Hu, Q Sun, K Xu, Y Jin, W Sang Journal of Cancer 12 (23), 7010, 2021 | 45 | 2021 |
| Anti-PD-1 therapy enhances the efficacy of CD30-directed chimeric antigen receptor T cell therapy in patients with relapsed/refractory CD30+ lymphoma W Sang, X Wang, H Geng, T Li, D Li, B Zhang, Y Zhou, X Song, C Sun, ... Frontiers in Immunology 13, 858021, 2022 | 43 | 2022 |
| Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infection Y Wang, Y Liu, X Tan, B Pan, J Ge, K Qi, H Cheng, J Cao, M Shi, Z Yan, ... Leukemia 34 (10), 2704-2707, 2020 | 42 | 2020 |
| MicroRNA‐181a, a potential diagnosis marker, alleviates acute graft versus host disease by regulating IFN‐γ production W Sang, C Zhang, D Zhang, Y Wang, C Sun, M Niu, X Sun, C Zhou, ... American journal of hematology 90 (11), 998-1007, 2015 | 41 | 2015 |
| MicroRNA-150 negatively regulates the function of CD4+ T cells through AKT3/Bim signaling pathway W Sang, C Sun, C Zhang, D Zhang, Y Wang, L Xu, Z Zhang, X Wei, B Pan, ... Cellular immunology 306, 35-40, 2016 | 33 | 2016 |
| An analysis of cardiac disorders associated with chimeric antigen receptor T cell therapy in 126 patients: a single-centre retrospective study K Qi, Z Yan, H Cheng, W Chen, Y Wang, X Wang, J Cao, H Zhang, ... Frontiers in Oncology 11, 691064, 2021 | 32 | 2021 |
| Piperlongumine selectively suppresses ABC-DLBCL through inhibition of NF-κB p65 subunit nuclear import M Niu, Y Shen, X Xu, Y Yao, C Fu, Z Yan, Q Wu, J Cao, W Sang, L Zeng, ... Biochemical and Biophysical Research Communications 462 (4), 326-331, 2015 | 30 | 2015 |
| The value of prognostic nutritional index (PNI) on newly diagnosed diffuse large B-cell lymphoma patients: a multicenter retrospective study of HHLWG based on propensity score … Z Shen, F Wang, C He, D Li, S Nie, Z Bian, M Yao, Y Xue, Y Wang, W Gu, ... Journal of Inflammation Research, 5513-5522, 2021 | 25 | 2021 |
| Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial M Shi, J Wang, H Huang, D Liu, H Cheng, X Wang, W Chen, Z Yan, ... Nature Communications 15 (1), 3371, 2024 | 22 | 2024 |
Ziyuan ShenAnhui Medical University在 utas.edu.au 的电子邮件经过验证
Ziyuan ShenAnhui Medical University在 utas.edu.au 的电子邮件经过验证